Forte Biosciences Files Q1 2025 10-Q
Ticker: FBRX · Form: 10-Q · Filed: May 15, 2025 · CIK: 1419041
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals, equity-plans
Related Tickers: FBRX
TL;DR
Forte Bio (FBRX) Q1 2025 10-Q filed. Financials and equity plans updated.
AI Summary
Forte Biosciences, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Tocagen Inc., is involved in pharmaceutical preparations. Their business address is in Dallas, Texas, and their fiscal year ends on December 31st. The filing includes information on various financial instruments and equity plans.
Why It Matters
This filing provides investors with an update on Forte Biosciences' financial position and operational details for the first quarter of 2025, crucial for understanding the company's performance and outlook.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Forte Biosciences faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 20250331 — Reporting Period End Date (Indicates the end of the fiscal quarter for which financial information is reported.)
- 1231 — Fiscal Year End (Specifies the end date of the company's fiscal year.)
Key Players & Entities
- Forte Biosciences, Inc. (company) — Filer of the 10-Q
- Tocagen Inc. (company) — Former name of Forte Biosciences, Inc.
- 20250331 (date) — End of the reporting period
- 3060 PEGASUS PARK DRIVE (location) — Business and mailing address
- DALLAS (location) — City of business and mailing address
- 75247 (location) — ZIP code of business and mailing address
FAQ
What is the primary business of Forte Biosciences, Inc.?
Forte Biosciences, Inc. is classified under Pharmaceutical Preparations (SIC code 2834).
When was the company formerly known as Tocagen Inc.?
The date of the name change from Tocagen Inc. to Forte Biosciences, Inc. was November 20, 2007.
What is the business address of Forte Biosciences, Inc.?
The business address is 3060 Pegasus Park Drive, Building 6, Dallas, TX 75247.
What is the SEC file number for this filing?
The SEC file number for this 10-Q filing is 001-38052.
What equity plans are mentioned in the filing for the period ending March 31, 2025?
The filing mentions the Employee Stock Purchase Plan and the Two Thousand Twenty-One Equity Incentive Plan for the period ending March 31, 2025.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding Forte Biosciences, Inc. (FBRX).